Radiotherapy instead of systemic therapy for metastatic kidney cancer

The use of radiotherapy for the treatment of metastatic renal cell carcinoma (RCC) is not routine. In a recent study, the use of radiotherapy to delay the use of medicines (systemic therapy) for patients with a small number of RCC metastases (oligometastatic) was assessed. There were 30 patient in the study, al of whom had […]

read more

Stereotactic radiotherapy for metastatic kidney cancer patients on TKIs

This phase 2 study looked at the use of stereotactic radiotherapy to treat metastatic renal cell carcinoma (RCC) in patients where the cancer had spread and there were a small number of metastases. These patients were on a tyrosine kinase inhibitor as the first or second medicine for their cancer. The aim of the study […]

read more

Stereotactic radiotherapy for metastatic kidney cancer

A paper published in the European Journal of Cancer earlier this month reports on the experience of six French hospitals with stereotactic radiotherapy (SRT) for metastatic renal cell carcinoma (RCC) between 2008 and 2015 . This retrospective study showed a 12-month local control rate of metastases of 82.9%. Twenty-five percent of patients with oligometastatic disease […]

read more

Stereotactic radiotherapy for the treatment of metastatic renal cell carcinoma

Results from a recent retrospective study from France, published in the journal Oncology,┬áhave shown that stereotactic radiotherapy is safe and effective for metastatic renal cell carcinoma (RCC) patients with metastases in one or two other parts of the body (oligometastatic or oligoprogressive). Stereotactic radiotherapy may also delay the start or change of systemic (drug) therapy. […]

read more
Showing all 4 results
  TOP